103 related articles for article (PubMed ID: 8459971)
1. Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report.
Surrey ES; Fournet N; Voigt B; Judd HL
Obstet Gynecol; 1993 Apr; 81(4):581-6. PubMed ID: 8459971
[TBL] [Abstract][Full Text] [Related]
2. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
Surrey ES; Voigt B; Fournet N; Judd HL
Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
[TBL] [Abstract][Full Text] [Related]
3. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
Surrey ES; Judd HL
J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
[TBL] [Abstract][Full Text] [Related]
4. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
Hornstein MD; Surrey ES; Weisberg GW; Casino LA
Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
[TBL] [Abstract][Full Text] [Related]
6. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial.
Fernandez H; Lucas C; Hédon B; Meyer JL; Mayenga JM; Roux C
Hum Reprod; 2004 Jun; 19(6):1465-71. PubMed ID: 15105403
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapies for endometriosis: implications for bone metabolism.
Dawood MY
Acta Obstet Gynecol Scand Suppl; 1994; 159():22-34. PubMed ID: 8209669
[TBL] [Abstract][Full Text] [Related]
9. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
Surrey ES; Hornstein MD
Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
[TBL] [Abstract][Full Text] [Related]
10. Current approaches to optimizing the treatment of endometriosis in adolescents.
Laufer MR
Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
[TBL] [Abstract][Full Text] [Related]
11. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
[TBL] [Abstract][Full Text] [Related]
12. Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty.
Yamaguchi K; Masuhara K; Yamasaki S; Fuji T; Seino Y
Bone; 2004 Jul; 35(1):217-23. PubMed ID: 15207760
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
14. Can we decrease breakthrough bleeding in patients with endometriosis on norethindrone acetate?
Muneyyirci-Delale O; Jalou S; Rahman M; Nacharaju V
Int J Fertil Womens Med; 2003; 48(1):32-6. PubMed ID: 12643518
[TBL] [Abstract][Full Text] [Related]
15. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group.
Agarwal SK; Hamrang C; Henzl MR; Judd HL
J Reprod Med; 1997 Jul; 42(7):413-23. PubMed ID: 9252932
[TBL] [Abstract][Full Text] [Related]
16. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis].
Mettler L
Zentralbl Gynakol; 2003; 125(7-8):267-75. PubMed ID: 14505262
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
18. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
19. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
Sebaldt RJ; Ioannidis G; Adachi JD; Bensen WG; Bianchi F; Cividino A; Gordon M; Kaminska E; Scocchia T; Petrie A; Stephenson GF; Goldsmith CH
J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
[TBL] [Abstract][Full Text] [Related]
20. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
